Last reviewed · How we verify
NCT05958017: COSTA
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
NA trial testing reSET in Stimulant Use Disorder in 500 participants. Currently enrolling.
31 January 2028
Quick facts
| Lead sponsor | University of Miami |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 500 |
| Start date | 4 March 2025 |
| Primary completion | 31 January 2028 |
| Estimated completion | 31 January 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- reSET
- Standard of care
Conditions studied
- Stimulant Use Disorder — all drugs for Stimulant Use Disorder →
- People Living With HIV — all drugs for People Living With HIV →
- reSET — all drugs for reSET →
Sponsor
University of Miami
Who can join
Adults 18 to 90, male only, with Stimulant Use Disorder or People Living With HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05958017
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of reSET
Trials testing the same drug.
- NCT03826966 — Comprehensive CBT (Cognitive Behavioral Therapy) Via reSET App · NA · completed
Other recruiting trials for Stimulant Use Disorder
Currently open trials in the same condition.
- NCT06790576 — Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder · Phase 1 · recruiting
- NCT06513156 — Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use · NA · recruiting
- NCT06444256 — Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder · Phase 2 · recruiting
- NCT06323837 — Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treat · Phase 2 · recruiting
- NCT05610072 — Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine) · EARLY_PHASE1 · recruiting
Other University of Miami trials
Trials by the same sponsor.
- NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
- NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
- NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
- NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
- NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05958017 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Miami
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05958017.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing